Immunotherapy, especially immune checkpoint inhibitors (ICIs) represented by programmed cell death protein-1 (PD-1) inhibitors, has significantly improved the prognosis of patients with advanced non-small cell lung cancer (NSCLC). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.